-
公开(公告)号：US20230303714A1
公开(公告)日：2023-09-28
申请号：US17991775
申请日：2022-11-21
发明人： Yuefeng Lu , Kurt Shanebeck , Lu Li , Lei Liu , Shiwen Zhang , Lan Yang , Jian-Feng Lu
IPC分类号： C07K16/30 , A61P35/00 , A61K47/68 , C07K14/765 , C07K14/55 , C07K14/54 , C07K16/28 , A61K31/282 , A61K31/337 , A61K39/395
CPC分类号： C07K16/3046 , A61P35/00 , A61K47/6863 , C07K14/765 , C07K14/55 , C07K14/5443 , C07K16/2809 , A61K31/282 , A61K31/337 , A61K39/39558 , C07K2317/31 , C07K2317/565 , C07K2317/24 , C07K2317/732 , C07K2317/734 , A61K2039/505
摘要： Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.
-
公开(公告)号：US20170327569A1
公开(公告)日：2017-11-16
申请号：US15593280
申请日：2017-05-11
发明人： Yuefeng Lu , Jian-Feng Lu
IPC分类号： C07K16/22 , C07K14/71 , C07K14/515 , A61K39/00
CPC分类号： C07K16/22 , A61K2039/505 , C07K14/515 , C07K14/71 , C07K2317/14 , C07K2317/51 , C07K2317/515 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C07K2319/32 , C07K2319/70
摘要： The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.
-
公开(公告)号：US20160083444A1
公开(公告)日：2016-03-24
申请号：US14857799
申请日：2015-09-17
申请人： AskGene Pharma, Inc.
发明人： Jian-Feng Lu , Yuefeng Lu , Aijun Wang , Donggou He , Kurt Shanebeck , Chen Yao
IPC分类号： C07K14/505 , C07K16/00
CPC分类号： C07K14/505 , A61K38/00 , C07K2319/30
摘要： The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.
摘要翻译： 本说明书公开了促红细胞生成素受体激动剂，包含这种促红细胞生成素受体激动剂的组合物和药物，用于促红细胞生成素受体激动剂及其组合物和药物的方法和用途，以及促红细胞生成素受体激动剂和用于治疗贫血的组合物和药物的方法和用途。
-
公开(公告)号：US11059885B2
公开(公告)日：2021-07-13
申请号：US16380852
申请日：2019-04-10
申请人： AskGene Pharma Inc.
发明人： Yuefeng Lu , Jian-Feng Lu
IPC分类号： C07K16/22 , A61K9/08 , A61K9/19 , C07K14/71 , C07K14/515
摘要： The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).
-
公开(公告)号：US20190106494A1
公开(公告)日：2019-04-11
申请号：US16111158
申请日：2018-08-23
发明人： Aijun Wang , Kurt Shanebeck , Donggou He , Chen Yao , Lu Li , Fang Xia , Yuefeng Lu , Jian-Feng Lu , Lan Yang
摘要： The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-PD-L1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.
-
公开(公告)号：US10077308B2
公开(公告)日：2018-09-18
申请号：US15620771
申请日：2017-06-12
发明人： Aijun Wang , Kurt Shanebeck , Donggou He , Chen Yao , Lu Li , Fang Xia , Yuefeng Lu , Jian-Feng Lu , Lan Yang
CPC分类号： C07K16/2827 , A61K2039/505 , A61P35/00 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/92
摘要： The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-PD-L1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.
-
公开(公告)号：US20180055944A1
公开(公告)日：2018-03-01
申请号：US15666515
申请日：2017-08-01
申请人： AskGene Pharma Inc.
发明人： Yuefeng Lu , Jian-Feng Lu , Lan Yang , Lu Li , Lei Liu , Shiwen Zhang
IPC分类号： A61K47/64 , A61K47/68 , C07K16/30 , C07K14/765 , A61K38/07
CPC分类号： A61K47/643 , A61K38/00 , A61K38/07 , A61K47/6817 , A61K47/6859 , C07K14/765 , C07K16/303 , C07K2317/56 , C07K2317/73 , C07K2317/77 , C07K2319/31 , C07K2319/33
摘要： The present invention relates to compositions and methods using an isolated chimeric molecule, wherein the isolated chimeric molecule comprises an antibody, one or more albumin motifs, optional peptide linkers, and two or more antibiotics or cytotoxic drug molecules conjugated to the unpaired cysteine residues, optionally through linkers. In one embodiment, each of the said albumin motifs in the isolated chimeric molecule contains 2 or more unpaired cysteine residues. In another embodiment, the said antibody in the isolated chimeric molecule targets antigens on cancer cells or drug-resistant bacteria. In another embodiment, the cancer cells have upregulated macropinocytosis. In another embodiment, the cancer cells contain one or more mutations in their RAS family genes. The compositions of the invention are used to treat drug-resistant bacterial infections and cancers, preferably the ones with upregulated macropinocytosis, and the ones containing one or more mutations in their RAS family genes.
-
公开(公告)号：US12043662B2
公开(公告)日：2024-07-23
申请号：US17374960
申请日：2021-07-13
申请人： AskGene Pharma Inc.
发明人： Yuefeng Lu , Jian-Feng Lu
CPC分类号： C07K16/22 , A61K9/08 , A61K9/19 , C07K2317/55 , C07K2317/622
摘要： The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).
-
公开(公告)号：US11746147B2
公开(公告)日：2023-09-05
申请号：US16741686
申请日：2020-01-13
发明人： Yuefeng Lu , Jian-Feng Lu
IPC分类号： C07K16/22 , C07K14/515 , C07K14/71 , A61K39/00
CPC分类号： C07K16/22 , C07K14/515 , C07K14/71 , A61K2039/505 , C07K2317/14 , C07K2317/51 , C07K2317/515 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C07K2319/32 , C07K2319/70
摘要： The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.
-
公开(公告)号：US20230135521A1
公开(公告)日：2023-05-04
申请号：US17049915
申请日：2019-04-22
申请人： AskGene Pharma Inc.
发明人： Yuefeng Lu , Jian-Feng Lu , Lu Li , Ming Li
摘要： The present specification discloses a pharmaceutical composition or stable aqueous formulations for erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, and methods and uses of erythropoietin receptor agonists and compositions. The present specification further discloses medicaments for treating an anemia in non-human mammals such as cats.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.028 秒)
